BioSpace News Archive

XVIVO Perfusion AB The results of the clinical trial conducted in Australia and New Zealand on XVIVO’s heart technology were earlier this week published in the prestigious scientific journal, The Journal of Heart and Lung Transplantation.

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will share new STAR-0215 data in a poster presentation at the upcoming American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting in Anaheim, California on November 11, 2023 at 12:35pm PST.

Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced data from three immuno-oncology pipeline programs at the 38th Annual Meeting of SITC taking place November 1 - 5, 2023 at the San Diego Convention Center in San Diego, CA.

BioStem Technologies Inc. announces that it has closed an oversubscribed private placement of common stock to accredited investors for an aggregate of 1,337,000 units at a price of $1.50 per Unit for gross proceeds of $2 million.

Oncocyte Corporation, a precision diagnostics company, announced that the company will host a conference call and webcast on Thursday, November 9, 2023, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to discuss its third quarter financial results and recent highlights.

Align Technology, Inc. announced that the company is scheduled to speak at the following upcoming financial conferences.

Therapeutics Corp. is pleased to report unprecedented activity of its next generation, personalized, off-the-shelf, cell-based breast and prostate cancer immunotherapies at the 2023 Society for Immunotherapy of Cancer annual meeting.

Cerus Corporation announced that the Company will participate in two upcoming investor conferences.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it is scheduled to participate in a fireside chat at the 2023 UBS Biopharma Conference on Wednesday, November 8th 2023 at 2:00 pm ET, as well as 1x1 meetings.

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its third quarter 2023 financial results after the market closes on Wednesday, November 8, 2023.